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ABSTRACT  
 
Objectives 
Approximately 9,000 people in the United Kingdom (UK) are affected by Huntington’s disease 
(HD). People with HD require ongoing health and social care support. There is a knowledge 
gap about costs of health and social care use associated with HD in the UK. This article 
estimates the economic cost in the UK. 
 
Methods 
Data on UK patients for the year 2013 was extracted from the European Huntington's Disease 
Network (EHDN) REGISTRY study, a full clinical dataset, including the full medical history 
and medication history for patients with HD. National unit costs for the price year 2013 were 
applied to health and social care services.  
 
Results 
Data were available for 131 people. The mean annual cost per person with HD was £21,605. 
The largest proportion of this cost (65%) was due to informal care (£14,085).  
 
Conclusions 
Informal care was the largest driver of costs across all stages of HD thus there is a need to 
also consider the needs of carers when planning services for people with HD. 
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INTRODUCTION 
Huntington’s disease (HD) is an inherited neurological disease, characterized by a 
progressive deterioration of movement, cognition and behaviour. Approximately 12 in every 
100,000 people in the United Kingdom (UK) are affected by HD [1]. Research has been 
conducted into the economic cost of other neurodegenerative conditions [2,3]. A European 
study of service use associated with HD has been undertaken [4], but costs were not 
estimated. One US study of the cost of HD was identified [5]. We present an estimate of the 
economic cost of HD in the UK.  
 
 
METHODS 
Data 
The European Huntington's Disease Network (EHDN) REGISTRY database [6] includes 
demographics, medical history and longitudinal information on patients with HD across 
Europe. Health and social care use is recorded using a Client Service Receipt Inventory 
(CSRI). It contains information on hospital and residential services, primary and community 
care, diagnostic tests, informal care, aids and adaptations to the home.  
 
Patients enrolled in the EHDN REGISTRY observational study provide informed, written 
consent for their anonymized data to be used for research purposes. Ethical approval was 
obtained from Bangor University School of Healthcare Sciences Ethics Committee (ref 2015-
15652). We analyzed data for UK patients from 01/01/2013 to 31/12/2013. Patients were 
categorized by Total Functional Capacity (TFC) score. A TFC score of 11-13 is classified as 
Stage I (earliest), 7-10 is Stage II, 3-6 is Stage III, 1-2 is Stage IV and a score of 0 is Stage V 
(latest). 
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Costing service use 
National unit costs for the price year 2013 were applied to the service use data by multiplying 
the frequency of contacts by a unit cost [7,8,9]. The REGISTRY database does not record the 
length of a contact, therefore a fixed length was assumed for each visit e.g. 12 minutes for a 
GP visit. Medication was costed by multiplying dose and duration of a medication course by 
its unit cost [9]. Informal care included personal care, help inside the home and help outside 
the home. The cost of informal care was estimated using the hourly rate of a home care 
worker as a replacement service (£24 per hour) [7]. Descriptive statistics are used to present 
the mean, standard deviation and median costs of service use, by TFC score. 
 
 
 
RESULTS 
CSRI data were available for 131 people (10% of REGISTRY patients in 2013). Our sample 
contained similar proportions of patients in each TFC stage compared to the larger 
REGISTRY sample, however our sample had no Stage V patients (3% of the REGISTRY 
sample were Stage V). The mean age was 50 (range 18-78). The sample contained 72 females 
and 59 males. 
 
 
Health and social care costs 
Mean annual costs per person in Stage I were £2,250, rising to £89,760 in Stage IV. The 
average cost across all stages was £21,605 per year (Table 1). This equates to £195 million 
per year in the UK. 
 
[TABLE 1] 
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DISCUSSION 
Average US costs have been estimated to be $4,947 (£3,150 in 2013 £) per person with HD 
in the early stage, rising to $22,582 (£14,378 in 2013 £) in the late stage for commercial 
patients and from $3,257 (£2,074 in 2013 £) in early stage Medicaid patients to $37,495 
(£23,873 in 2013 £) in late stage Medicaid patients [5]. In the US study more Medicaid 
patients were in long-term care compared to commercial patients, thus driving the cost 
differences; the authors noted that this may be due to Medicaid patients being at a later 
disease stage or because data on long-term care for the commercial patients is less complete 
[5]. In our study, the average annual cost per person was £21,605, which is comparable to the 
cost of dementia in the UK (£32,242 per person) [10]. Looking at disease severity, our range 
was greater than in Divino et al. [5], at £2,250 per person in the earliest stage of HD and 
£89,760 in the later stages. However, we note there are substantial differences between the 
US and UK healthcare systems, and the categories of costs included in the respective studies, 
therefore our findings are only applicable to UK patients. 
 
As would be expected with a degenerative condition, costs increased by disease severity, 
presenting the case for investing in care and support for people with in the earlier stages to 
keep them functioning well. The appropriate time to introduce and subsequently increase 
social care packages to support people with HD and their informal carers is likely to vary 
between individuals, but our study has identified that increased social care support is likely to 
be needed during Stages III and IV of HD. Informal care was the largest driver of costs, thus 
there is a need to consider the needs of carers as well as people with HD. While the study 
population was representative of the larger REGISTRY sample in terms of TFC stratification, 
we are unable to say whether service use data were missing at random, and therefore whether 
there is inherent bias in our cost estimates due to under-reporting of service use. In particular, 
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our study had no people in Stage V. REGISTRY data is collected by interviews in outpatient 
visits, which may lead to under-representation of people living in long-term care. As such, 
the estimated costs of HD presented here may be even higher in practice. 
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Table 1: Mean (SD) and median annual costs  
Category All stages 
(n=131) 
Stage I: TFC 11-13 
(n=43) 
Stage II: TFC 7-10 
(n=37) 
Stage III: TFC 3-6 
(n=38) 
Stage IV: TFC 1-2 
(n=13) 
 Mean SD Median Mean SD Median Mean SD Median Mean SD Median Mean SD Median 
Primary/ 
community 
care  
£2,680.24  £5,768.72 £886.00 £763.35 £758.57 £588.00 £1,709.89  £1,813.60 £1,156.00 £3,813.74 £6,752.50  £1,106.00 £8,469.23  £12,312.59 £2112.00 
Hospital/ 
residential 
care  
£2,436.76  £9,455.52 £0 £99.40  £160.93 £0 £1,800.27 £6,783.42 £0 £2,236.31  £6,673.06 £238.00 £12,565.56  £23,686.39 £314.00 
Investigations/ 
diagnostic 
tests 
£19.96  £87.30 £0 £5.16  £17.30 £0 £23.35  £75.19 £0 £35.42 £141.14  £0 £14.15 £38.99 £0.00 
Medication £851.42  £1,675.51 £204.40 £306.53 £883.76 £18.25 £730.14 £1,262.71 £261.78 £858.97  £823.49 £623.27 £2,976.83 £3,847.27 £1653.45 
Informal care £14,085.24  £30,391.87 £0 £1,073.86  £5,558.46 £0 £4,941.41  £8,561.39 £0 £21,051.79  £19,847.84 £18,096.00 £62,784.00 £69,831.12 £38,688.00 
Adaptations/ 
aids 
£1,531.46  £4,837.66 £0 £1.77 £11.59 £0 £2,662.70  £7,424.02 £0 £1,675.68  £4,186.72 £0 £2,949.85  £4,422.71 £162.00 
TOTAL £21,605.08  £36,373.51 £3515.35 £2,250.06  £5,922.11 £736.95 £11,867.76  £15,749.52 £4,944.58 £29,671.91  £23,597.03 £26,814.41 £89,759.62  £69,829.63 £110,939.60 
 
